Table 1.

Initial clinical and laboratorial characteristics.

Characteristics	Group 1 (N = 20)	Group 2 (N = 62)	Group 3 (N = 33)	p-value
Sex (F/M)	3/17	19/43	9/24	NS
Target height (cm)	161.9 ± 9	165.6 ± 9.6	166.1 ± 7.1	NS
Target height SDS	−1.7 ± 0.9	−1 ± 1.1	−1 ± 0.8	<0.05*
Peak GH to ITT(μg/L)	19.4 ± 8.3	3.6 ± 2.6	6.4 ± 8.9	<0.05†
Peak GH to CT (μg/L)	18.7 ± 15.9	4 ± 3.1	9 ± 11.8	<0.05†

^*p < 0.05 (group 1 vs. other groups).

^†p < 0.05 (between all groups).

Group 1: children diagnosed with FSS or CDGP; Group 2: children who gained 0.3 SD in height after 1 year of rhGH treatment; Group 2: children who gained <0.3 SD in height after 1 year of rhGH treatment. F, Female; M, Male; IGF-1, Insulin-like Growth Factor I; ITT, Insulin Tolerance Test; CT, Clonidine Test; NS, Not Significant; FSS, Familial Short Stature; CDGP, Constitutional delay of growth and puberty; rhGH, Recombinant Human Growth Hormone.